Anticoagulants & thrombolytics-Mata Flashcards
1
Q
Heparin
A
MOA: binds to endogenous antithrombin III and irreversibly inactives thrombin
- Given parenterally
- Speeds up antithrombin action 1000x
2
Q
Unfractionated heparin
A
- Begins working immediately
- Used in combo w/thrombolytics for revascularization
- Does NOT cross placental barrier so ok for preggos
- IV or SC to avoid hematoma
- Speeds up activity on factor XA
- Prophylaxis for DVT
3
Q
Low Molecular Weight (LMW) Heparin & Foundparinux
A
- Binds antithrombin and has same inhibitory effect on XA as unfractionated heparin
- More selective (no effect on thrombin)
- IV or SC (longer half-life after SC)
4
Q
Heparin toxicity
A
- Increased bleeding time is common adverse effect of heparin and related molecules
- Can lead to hemorrhagic stroke
5
Q
Protamine
A
- Lessens risk of serious bleeding w/heparin
6
Q
Major Side Effects of Heparin
A
- Non-immune mediated Heparin–associated thrombocytopenia (HAT) Type I - common; direct run b/n heparin and platelets
- Immune-mediated Heparin-induced thrombovytopenia (HIT) Type II - FATAL
7
Q
Rivaroxaban
A
- MOA: direct inhibitor of factor XA that inhibits both free and clot bound factor XA
- Uses: prophylaxis for DVT, reducing stroke risk
- Risk of thrombotic events upon premature discontinuation
8
Q
Lepirudin
A
- Direct thrombin inhibitor
- Recombinant form of hirudin
- Alternative to heparin
- Irreversibly binds and inhibits free and fibrin bound thrombin
- Cons: prolonged half-life in renal compromised pts
9
Q
Desirudin & Bivalirudin
A
- Direct thrombin inhibitor
- Modified forms of hirudin
- Bivalrudin also inhibits platelet activation
10
Q
Direct thrombin inhibitors
A
Based on leech protein hirudin that directly binds to thrombin to prevent thrombin-mediated activation of fibrinogen and factor XIII
11
Q
Argatroban
A
- Small molecule direct thrombin inhibitor (binds only to active site of thrombin)
- Used for treatment of patients with heparin-Induced thrombocytopenia (HIT)
- Safe to be given in renal insufficiency (excrete via biliary route)
12
Q
Dabigatran
A
- Small molecule direct thrombin inhibitor (binds only to active site of thrombin)
- No need to monitor blood levels
- Greater predictive PK and PD
- No dose adjustments
- No significant drug-interactions
13
Q
Warfarin
A
- MOA: inhibits Vitamin K epoxide reductase needed for coagulation cascade
- Affects factor II, VII, IX & X
- Mimics Vitamin K (Vit K can also reverse it)
- SE: bleeding, transient period of hypercoagulaility, inhibition of protein C
- Narrow therapeutic range
14
Q
Tissue Plasminogen Activator (tPA) (aka - Thrombolytic Agents)
A
- An enzyme that binds to fibrin in a newly formed clot and directly converts plasminogen to plasmin
- Toxicity can cause cerebral hemorrhage
- Increases risk of bleeding with warfarin, heparin, aspirin
15
Q
Alteplase
A
- Thrombolytic (fibrinolytic) Agent
- Normal human tPA
16
Q
Reteplase
A
- Thrombolytic (fibrinolytic) Agent
- Mutated tPA w/similar effects but faster onset of action and longer duration of action